Want to see TSE:ZRO full AI Analyst Report?
ZRO Stock Chart & Stats
C$0.06
-C$0.04(-50.00%)
At close: 4:00 PM EDT
C$0.06
-C$0.04(-50.00%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.14
Previous CloseN/A
Volume8.50K
Average Volume (3M)3.67K
Market Cap
C$3.13M
Enterprise ValueC$1.95
Total Cash (Recent Filing)C$19.93K
Total Debt (Recent Filing)C$7.52M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding34,768,887
10 Day Avg. Volume6,200
30 Day Avg. Volume3,672
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Antimicrobial And Odor-control FocusBiosenta is focused on a defined product area addressing microbial growth and odor across commercial and consumer uses. That specialization can support durable relevance if its formulations gain adoption, because the underlying needs span multiple materials, environments, and end markets.
Multiple Commercialization PathwaysThe stated model allows Biosenta to commercialize technologies through both direct products and partner-led channels. This flexibility could broaden market access and create more than one route to monetization, including possible royalties or licensing fees, if commercial adoption develops.
Moderating Cash BurnAlthough cash generation remains negative, the reported moderation in burn versus 2024 is a constructive operational trend. Continued improvement could extend available resources and reduce the pace of funding needs, provided the company can sustain this progress while developing its commercial business.
Bears Say
Severely Stressed Balance SheetDebt that is large relative to the asset base, together with negative and worsening shareholders’ equity, indicates very limited financial flexibility. This weak capital structure can constrain investment, increase solvency pressure, and make it harder to fund commercialization without external support.
Persistent Cash ConsumptionBiosenta is still consuming cash rather than generating it, despite some improvement in burn. Persistent negative operating and free cash flow suggests that ongoing activities are not self-funding and may require external capital, limiting resilience and the ability to invest consistently in growth.
Contracting Revenue And Deep LossesA shrinking revenue base combined with negative gross profit and large operating and net losses shows that the business has not yet established a sustainable earnings model. Continued weak margins can restrict reinvestment, reduce operating flexibility, and delay progress toward self-funded growth.
Biosenta Inc News
ZRO FAQ
What was Biosenta Inc’s price range in the past 12 months?
Biosenta Inc lowest stock price was C$0.01 and its highest was C$0.14 in the past 12 months.
What is Biosenta Inc’s market cap?
Biosenta Inc’s market cap is C$3.13M.
When is Biosenta Inc’s upcoming earnings report date?
Biosenta Inc’s upcoming earnings report date is Feb 02, 2027 which is in 127 days.
How were Biosenta Inc’s earnings last quarter?
Biosenta Inc released its earnings results on Aug 28, 2026. The company reported -C$0.048 earnings per share for the quarter.
Is Biosenta Inc overvalued?
According to Wall Street analysts Biosenta Inc’s price is currently Overvalued.
Does Biosenta Inc pay dividends?
Biosenta Inc does not currently pay dividends.
What is Biosenta Inc’s EPS estimate?
Biosenta Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosenta Inc have?
Biosenta Inc has 34,768,887 shares outstanding.
What happened to Biosenta Inc’s price movement after its last earnings report?
Biosenta Inc reported an EPS of -C$0.048 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosenta Inc?
Currently, no hedge funds are holding shares in TSE:ZRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biosenta Inc
Biosenta Inc., a Toronto-based Canadian firm established in 1986, specializes in the development, manufacturing, and sale of antimicrobial chemical compounds for both residential and commercial applications throughout the country. The company is actively working on "true," an innovative, dual-action disinfectant with potent antimicrobial capabilities, engineered to instantaneously eradicate viruses, bacteria, mold, and various germs upon contact. Additionally, Biosenta Inc. intends to produce and distribute "Tri-Filler," an antimicrobial additive designed for bulking and filling purposes.
Technical Analysis
BioNeutra Global
―
Lifeist Wellness
―
Psyched Wellness
―
Happy Supplements Inc.
―
Pure to Pure Beauty Inc.
―